Core Viewpoint - The stock trading activity of Dezhan Health (000813) has been notably active, with market focus on capital flow and margin trading data [1] Group 1: Stock Performance - The stock price closed at 3.87 yuan, down 1.28% for the day, with a cumulative decline of 1.78% over the past five days, underperforming the market index [1] - The technical analysis indicates a recent downward trend in stock price, with a pressure level at 4.21 yuan and a support level at 3.73 yuan according to the 20-day Bollinger Bands [1] Group 2: Capital Flow - Main capital showed a net outflow of 18.73 million yuan, accounting for 20.27% of the total trading volume, while retail investors experienced a net inflow of 12.13 million yuan, reflecting short-term market divergence [1] Group 3: Margin Trading - The net margin buy was 1.30 million yuan, with a margin balance of 331 million yuan, showing a slight increase of 0.37% from the previous day, although it remains at a relatively low level over the past year [1] - In comparison to previous data, there was a net margin sell of 13.26 million yuan, with a margin balance of 338 million yuan, indicating fluctuations in recent margin trading sentiment [1]

Core Viewpoint - The report highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, indicating a significant increase in the number of large-scale industrial companies and their contribution to the national economy [1]. Group 1: Industrial Growth in Xinjiang - As of January to December 2025, the number of industrial enterprises in Xinjiang is projected to be 5,576, which represents an increase of 438 enterprises compared to the previous year, marking a year-on-year growth of 8.52% [1]. - The industrial enterprises in Xinjiang account for 1.06% of the total number of such enterprises in the country [1]. Group 2: Industry Research and Consulting - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in deep industry research and providing comprehensive consulting services, including industry research reports and feasibility studies [1]. - The firm emphasizes its commitment to delivering high-quality services and market insights to empower investment decisions [1].

Group 1 - The company, Dezhan Health, forecasts a significant loss of between 175 million to 350 million yuan for 2025, marking the largest loss in five years, compared to a loss of 20.41 million yuan in 2024 [1] - From 2021 to 2025, the company has reported losses in four out of five years, with a profit of 83 million yuan only in 2023 [1] - The company attributes the expected losses to ongoing investments in nurturing business and R&D, the impact of centralized procurement policies on revenue, and impairment provisions for long-term equity investments and goodwill [1] Group 2 - Dezhan Health, originally Tianshan Textile, is the only listed pharmaceutical and health company within the Xinjiang state-owned asset system [1] - On September 16, 2025, the company underwent a management change, appointing Wei Zheming as chairman and Liu Wei as co-chairman and general manager, along with several other executive appointments [1] - On December 13, 2025, Wang Shubin, who had been in the role for less than three months, resigned from his position as vice president due to personal reasons [2] - The company is involved in a lawsuit related to a contract dispute between its former controlling shareholder and another company, which has been filed in the Beijing Third Intermediate People's Court [2] - Dezhan Health is among over 12 pharmaceutical companies implicated in a bribery case involving a hospital's pharmacy director [2][3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日-2025年12月31日 （二）业绩预告情况：预计净利润为负值 ■ 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就业绩预告有 关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面不存在 分歧。 三、业绩变动原因说明 2025年，公司围绕生物医药核心业务，立足科技创新战略，持续推动公司创新转型升级。公司创新药研 发稳步推进，心理康复医院正式投入运营。但受（1）公司对培育期业务及研发创新的持续投入；（2） 集采政策对公司营收的影响；及（3）公司基于谨慎性原则对长期股权投资、商誉、其他应收款等计提 减值的影响，本报告期公司预计净利润为负值。 四、风险提示 （一）本次业绩预告是公司财务部门初步测算的结果，公司2025年度具体财务数据以正式披露的2025年 年度报告为准。 （二）公司将严格按照相关法律法规、规范性文件的规定 ...

Financial Performance - The company expects a net profit loss between CNY 17,500,000 and CNY 35,000,000 for the fiscal year 2025, compared to a loss of CNY 2,041,310 in the same period last year[2] - The net profit loss after deducting non-recurring gains and losses is also projected to be between CNY 17,500,000 and CNY 35,000,000, compared to a loss of CNY 2,369,670 in the previous year[2] - Basic earnings per share are expected to be between CNY -0.0827 and CNY -0.1654, compared to a loss of CNY 0.0095 per share in the prior year[2] Business Focus and Strategy - The company is focusing on core biopharmaceutical business and technology innovation, with ongoing development of innovative drugs and the operation of a psychological rehabilitation hospital[4] - The anticipated losses are attributed to continued investment in nurturing business and R&D innovation, the impact of centralized procurement policies on revenue, and impairment provisions for long-term equity investments and goodwill[4]

Core Insights - On January 29, a total of 3,766 stocks in the A-share market received financing funds for purchase, with 662 stocks having purchase amounts exceeding 100 million [1] Financing Purchase Amounts - The top three stocks by financing purchase amount were Zijin Mining, Bluefocus, and Northern Rare Earth, with amounts of 4.113 billion, 3.26 billion, and 2.486 billion respectively [1] Financing Purchase Proportions - Five stocks had financing purchase amounts accounting for over 30% of the total transaction amount on that day. The top three were Dezhan Health, Huilong Shares, and Shenzhen Airport, with proportions of 47.08%, 37.87%, and 37.33% respectively [1] Net Financing Purchases - A total of 52 stocks had net financing purchases exceeding 100 million. The top three in net financing purchases were Zijin Mining, Tianfu Communication, and Bluefocus, with net amounts of 1.042 billion, 891 million, and 869 million respectively [1]

Core Viewpoint - Dezheng Health announced that it will hold the third extraordinary general meeting of shareholders on December 30, 2025, to review and approve multiple proposals, including the "Proposal on the Formulation of the Company's Director Allowance Scheme" [2] Group 1 - The meeting is scheduled for December 30, 2025 [2] - The agenda includes the review of the director allowance scheme [2]

德展大健康股份有限公司 关联交易决策制度 （2025 年 12 月修订） 第一章 总则 第一条 为维护德展大健康股份有限公司（以下简称"公司"或"本公司"）、 股东和相关利益者的合法权益，规范关联交易，控制关联交易风险，保证公司与 关联方之间订立的关联交易合同符合公平、公正、公开的原则，确保公司的关联 交易行为不损害公司和全体股东利益，根据《中华人民共和国公司法》《深圳证 券交易所股票上市规则》（以下简称"《上市规则》"）、《深圳证券交易所上 市公司自律监管指引第 7 号——交易与关联交易》等有关法律法规、规范性文件 和《德展大健康股份有限公司章程》（以下简称"《公司章程》"）的相关规定， 制定本制度。 第二条 公司与关联人进行交易时，应遵循以下基本原则： （一）平等、自愿、等价、有偿的原则； （二）公平、公开、公允的原则； （三）对于必需的关联交易，严格依照法律法规和规范性文件加以规范； （四）在必需的关联交易中，关联股东和关联董事应当执行《公司章程》规 定的回避表决制度； （五）处理公司与关联人之间的关联交易，不得损害公司及股东的合法权益， 必要时应聘请独立财务顾问或专业评估机构发表意见和报告； 1 （二 ...

德展大健康股份有限公司 投资管理制度 （2025 年 12 月修订） 第一章 总则 第一条 为了进一步规范德展大健康股份有限公司（以下简称"公司"）的投 资决策程序，建立系统、完善的投资决策机制，确保科学、规范、透明地做出投 资决策，有效防范投资风险，保障公司和股东的利益。根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《深圳证券交易所股票上市规则》（以下简称"《上市规则》"）及《公司章程》等 规定，特制定本制度。 第二条 本制度适用于公司及公司全资、控股子公司（以下统称"子公司"） 一切投资活动（包括对子公司的投资）。 第三条 本制度所称投资指公司在境内外进行的以盈利或保值增值为目的的 除在境内外证券市场投资有价证券（包括新股配售或者申购、股票二级市场投资） 的投资行为。现金管理（商业银行理财及其他理财工具）另设有单独的制度。 第四条 投资应遵循的基本原则： （一）必须遵守国家相关法律、法规的规定，符合国家的产业政策； （二）必须立足主业，符合公司发展战略和规划要求，合理配置企业资源， 有利于拓展公司主营业务，扩大再生产，有利于公司的可持续发展 ...

德展大健康股份有限公司 对外担保管理制度 （2025 年 12 月修订） 第一章 总则 第一条 为了维护投资者的合法利益，规范德展大健康股份有限公司（以下 简称"公司"）的对外担保行为，控制公司资产运营风险，促进公司健康稳定地 发展，根据《中华人民共和国公司法》《中华人民共和国民法典》《深圳证券交易 所股票上市规则》（以下简称"《上市规则》"）、《上市公司监管指引第 8 号——上 市公司资金往来、对外担保的监管要求》《深圳证券交易所上市公司自律监管指 引第 1 号——主板上市公司规范运作》等有关法律法规、规范性文件以及《德展 大健康股份有限公司章程》（以下简称"《公司章程》"）的相关规定，制定本制度。 第二条 本制度所称对外担保是指公司以第三人身份为他人提供保证、抵押 或质押的行为，包括公司对控股子公司、参股公司的担保。具体种类包括但不限 于借款担保、银行开立信用证和银行承兑汇票担保、开具保函提供担保以及为其 他债务提供担保。 公司控股子公司为公司合并报表范围之外的主体提供担保的，视同公司对外 担保。 第七条 公司为他人提供担保应当遵循平等、自愿、公平、诚信、互利的原 则。任何单位和个人不得强令公司为他人提供 ...